Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413693 | 0.87 | BAZ2B (0.46) | MCL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL10110861 | 0.83 | MAPT (0.38) | MCL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL6512078 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1HPGDMAPTCNR2 | |
| SCHEMBL13682851 | 0.83 | MAPK1 (0.46) | MCL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL29904566 | 0.80 | SLC22A12 (0.40) | MCL1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29030290 | 0.77 | CNR2 (0.43) | MCL1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL2053661 | 0.77 | CNR2 (0.46) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4411023 | 0.75 | ALDH1A1 (0.49) | MCL1HSD17B10KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL31705791 | 0.74 | GRM4 (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL17440399 | 0.73 | DAO (0.56) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | claimed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
| WO-2007103584-A2 | POLYAMIDES FOR TREATING HUMAN PAPILLOMA VIRUS | NANOVIR, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20050009054-A1 | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004099131-A2 | COMPOUNDS HAVING A FUSED, BICYCLIC MOIETY FOR BINDING TO THE MINOR GROOVE OF DSDNA | PHARMACIA CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | MCL1 1191/4885HSD17B10 3379/4885KDM4E 2155/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | MCL1 1039/4885HSD17B10 3315/4885KDM4E 1638/4885 |
| US-20050009054-A1 | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA | PCNA, POLM, PBRM1 | MCL1 1506/4885HSD17B10 3287/4885KDM4E 3756/4885 |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | MCL1 2359/4885HSD17B10 1662/4885KDM4E 225/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | MCL1 1282/4885HSD17B10 3858/4885KDM4E 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.